Inhalation therapy, a second wind for research [ Return towards  An innovative company  ]

A major stake today, the development of inhalation therapies gives hope to many individuals suffering from respiratory diseases. Involving the administration of drugs in gaseous form, these therapies allow patients to breathe more easily while reducing their pain, in addition to helping patients recover more rapidly after surgery. Used in hospitals, they may also be employed at home, promising a real improvement in the daily lives of patients.

A non-profit group located in Boston (United States), CIMIT comprises clinicians, scientists, and engineers. Together, they envision innovative technological solutions with direct medical applications to improve patients’ quality of life – a concern shared by Air Liquide, a forerunner in the respiratory care market. The Group has thus committed to furthering CIMIT’s goals and will lend support to its new research program on inhalation therapy to the tone of 1.5 million dollars.